T2 Biosystems, Inc. (TTOO) Scheduled to Post Quarterly Earnings on Monday
T2 Biosystems, Inc. (NASDAQ:TTOO) will be announcing its earnings results after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
T2 Biosystems (NASDAQ:TTOO) last released its quarterly earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). The firm had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.79 million. T2 Biosystems had a negative return on equity of 178.83% and a negative net margin of 1,473.71%. On average, analysts expect T2 Biosystems to post $-1.93 EPS for the current fiscal year and $-1.72 EPS for the next fiscal year.
T2 Biosystems, Inc. (NASDAQ TTOO) traded down 0.49% during trading on Monday, hitting $4.03. 13,140 shares of the stock traded hands. T2 Biosystems, Inc. has a one year low of $2.50 and a one year high of $7.18. The stock’s market cap is $123.98 million. The company has a 50-day moving average price of $4.56 and a 200 day moving average price of $3.90.
A number of research analysts have issued reports on the company. Zacks Investment Research cut T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. ValuEngine raised T2 Biosystems from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 13th. Finally, HC Wainwright assumed coverage on T2 Biosystems in a report on Wednesday, October 18th. They set a “buy” rating and a $8.00 price objective for the company. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.00.
About T2 Biosystems
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.